首页|A pilot clinical study to evaluate feasibility of using single patient classifier as a prognostic test in stage Ⅱ-Ⅲ gastric cancer patients

A pilot clinical study to evaluate feasibility of using single patient classifier as a prognostic test in stage Ⅱ-Ⅲ gastric cancer patients

扫码查看
原文链接
  • NETL
  • NSTL
  • 万方数据
Objective:Precision medicine approaches emphasize the importance of reliable prognostic tools for guiding individualized therapy decisions.In this study,we evaluated the clinical feasibility of the single patient classifier(SPC)test,a new clinical-grade prognostic assay,in stage Ⅱ-Ⅲ gastric cancer patients.Methods:A prospective multicenter study was conducted,involving 237 patients who underwent gastrectomy between September 2019 and August 2020 across nine hospitals.The SPC test was employed to stratify patients into risk groups,and its feasibility and performance were evaluated.The primary endpoint was the proportion of the cases in which the test results were timely delivered before selecting postoperative treatment.Furthermore,3-year disease-free survivals of risk groups were analyzed.Results:The SPC test met the primary endpoint criteria.The 99.5％of SPC tests were timely delivered to hospitals before the postoperative treatment started.In a clinical setting,the median time from the specimen transfer to laboratory to the result delivery to hospital was 4 d.Furthermore,3-year disease-free survivals were significantly different between risk groups classified with SPC tests.Conclusions:This study highlights the SPC test's feasibility in offering crucial information timely delivered for making informed decisions regarding postoperative treatment strategies.It also provides evidence to support the implementation of a future prospective clinical trial aimed at evaluating the clinical utility of the SPC test in guiding personalized treatment decisions for gastric cancer patients.

Prognostic testadvanced gastric canceradjuvant chemotherapyfeasibilitygastrectomy

Ji Yeong An、Sung Eun Oh、Soomin Ahn、Hyoung-Ⅱ Kim、Yoo Min Kim、Minah Cho、Keun Won Ryu、Hong Man Yoon、Young Kyu Park、In Gyu Kwon、Sung Hoon Noh、Kyung Hee Lee、In Cho、Myoung Won Son、Jong Won Kim、Young-Woo Kim

展开 >

Department of Surgery,Samsung Medical Center,Sungkyunkwan University School of Medicine,Seoul 06351,Republic of Korea

Department of Pathology and Translational Genomics,Samsung Medical Center,Sungkyunkwan University School of Medicine,Seoul 06351,Republic of Korea

Department of Surgery,Yonsei University College of Medicine,Seoul 03722,Republic of Korea

Gastric Cancer Center,Yonsei Cancer Center,Yonsei University Health System,Seoul 03722,Republic of Korea

Center for Gastric Cancer,National Cancer Center,Goyang 10408,Republic of Korea

Department of Surgery,Chonnam National University Hwasun Hospital,Chonnam National University College of Medicine,Gwangju 58128,Republic of Korea

Department of Surgery,Gangnam Severance Hospital,Yonsei University College of Medicine,Seoul 06273,Republic of Korea

Department of Hematology-Oncology,Yeungnam University Medical Center,Daegu 42415,Republic of Korea

Department of Surgery,Soonchunhyang University College of Medicine,Bucheon 14584,Republic of Korea

Department of Surgery,Soonchunhyang University Cheonan Hospital,Soonchunhyang University College of Medicine,Cheonan 31151,Republic of Korea

Department of Surgery,Chung-Ang University Hospital,Chung-Ang University College of Medicine,Seoul 06973,Republic of Korea

展开 >

Novomics(Seoul,Korea)

2024

10.21147/j.issn.1000-9604.2024.04.02

中国癌症研究(英文版)
中国抗癌协会 北京市肿瘤研究所

中国癌症研究(英文版)

CSTPCD
影响因子：1.592
ISSN：1000-9604
年,卷(期)：2024.36(4)